Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Ulf Landmesser
Based on 51 articles published since 2010
(Why 51 articles?)
||||

Between 2010 and 2020, U. Landmesser wrote the following 51 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3
1 Guideline 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. 2018

Landmesser, Ulf / Chapman, M John / Stock, Jane K / Amarenco, Pierre / Belch, Jill J F / Borén, Jan / Farnier, Michel / Ference, Brian A / Gielen, Stephan / Graham, Ian / Grobbee, Diederick E / Hovingh, G Kees / Lüscher, Thomas F / Piepoli, Massimo F / Ray, Kausik K / Stroes, Erik S / Wiklund, Olov / Windecker, Stephan / Zamorano, Jose Luis / Pinto, Fausto / Tokgözoglu, Lale / Bax, Jeroen J / Catapano, Alberico L. ·Department of Cardiology, Charite Universitätsmedizin Berlin, Berlin Institute of Health (BIH), German Center of Cardiovascular Research (DZHK), Hindenburgdamm 30, 12203 Berlin, Germany. · National Institute for Health and Medical Research (INSERM), University of Pierre and Marie Curie, Pitié-Salpêtrière Hospital, Paris, France. · European Atherosclerosis Society, Gothenburg, Sweden. · Paris-Diderot-Sorbonne University and Department of Neurology and Stroke Centre, Bichat Hospital, Paris, France. · Institute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee, UK. · Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, and Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden. · Lipid Clinic, Point Medical, and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France. · Division of Cardiovascular Medicine, Division of Translational Research and Clinical Epidemiology, Wayne State University School of Medicine, Detroit, MI, USA. · Department of Internal Medicine III, Martin-Luther-University Halle/Wittenberg, University Hospital, Halle/Saale, Germany. · Trinity College, Dublin, Ireland. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. · University Heart Center, Department of Cardiology, University Hospital Zurich, and Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland. · Heart Failure Unit, Cardiac Department, G Da Saliceto Hospital, Piacenza, Italy. · Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College, London, UK. · Sahlgrenska University Hospital, Gothenburg, Sweden. · Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland. · Department of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain. · Cardiology Department, CCUL, CAML, Faculdade de Medicina, Universidade de Lisboa, Portugal. · Department of Cardiology, Hacettepe University, Ankara, Turkey. · Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands. · Department of Pharmacological and Biomolecular Sciences, University of Milan and Multimedica IRCSS Milano, Italy. ·Eur Heart J · Pubmed #29045644.

ABSTRACT: -- No abstract --

2 Guideline 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2014

Kolh, Philippe / Windecker, Stephan / Alfonso, Fernando / Collet, Jean-Philippe / Cremer, Jochen / Falk, Volkmar / Filippatos, Gerasimos / Hamm, Christian / Head, Stuart J / Jüni, Peter / Kappetein, A Pieter / Kastrati, Adnan / Knuuti, Juhani / Landmesser, Ulf / Laufer, Günther / Neumann, Franz-Josef / Richter, Dimitrios J / Schauerte, Patrick / Sousa Uva, Miguel / Stefanini, Giulio G / Taggart, David Paul / Torracca, Lucia / Valgimigli, Marco / Wijns, William / Witkowski, Adam / Anonymous7870804 / Zamorano, Jose Luis / Achenbach, Stephan / Baumgartner, Helmut / Bax, Jeroen J / Bueno, Héctor / Dean, Veronica / Deaton, Christi / Erol, Çetin / Fagard, Robert / Ferrari, Roberto / Hasdai, David / Hoes, Arno W / Kirchhof, Paulus / Knuuti, Juhani / Kolh, Philippe / Lancellotti, Patrizio / Linhart, Ales / Nihoyannopoulos, Petros / Piepoli, Massimo F / Ponikowski, Piotr / Sirnes, Per Anton / Tamargo, Juan Luis / Tendera, Michal / Torbicki, Adam / Wijns, William / Windecker, Stephan / Anonymous7880804 / Sousa Uva, Miguel / Achenbach, Stephan / Pepper, John / Anyanwu, Anelechi / Badimon, Lina / Bauersachs, Johann / Baumbach, Andreas / Beygui, Farzin / Bonaros, Nikolaos / De Carlo, Marco / Deaton, Christi / Dobrev, Dobromir / Dunning, Joel / Eeckhout, Eric / Gielen, Stephan / Hasdai, David / Kirchhof, Paulus / Luckraz, Heyman / Mahrholdt, Heiko / Montalescot, Gilles / Paparella, Domenico / Rastan, Ardawan J / Sanmartin, Marcelo / Sergeant, Paul / Silber, Sigmund / Tamargo, Juan / ten Berg, Jurrien / Thiele, Holger / van Geuns, Robert-Jan / Wagner, Hans-Otto / Wassmann, Sven / Wendler, Olaf / Zamorano, Jose Luis / Anonymous7890804 / Anonymous7900804. ·(Belgium) philippe.kolh@chu.ulg.ac.be stephan.windecker@insel.ch. · (Switzerland) philippe.kolh@chu.ulg.ac.be stephan.windecker@insel.ch. · (Spain). · (France). · (Germany). · (Switzerland). · (Greece). · (Netherlands). · (Finland). · (Austria). · (Portugal). · (UK). · (Italy). · (Belgium). · (Poland). · (Turkey). · (Israel). · (Germany/UK). · (Czech Republic). · (Norway). · (USA). · (UK/Germany). ·Eur J Cardiothorac Surg · Pubmed #25173601.

ABSTRACT: -- No abstract --

3 Guideline 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2014

Anonymous7760804 / Windecker, Stephan / Kolh, Philippe / Alfonso, Fernando / Collet, Jean-Philippe / Cremer, Jochen / Falk, Volkmar / Filippatos, Gerasimos / Hamm, Christian / Head, Stuart J / Jüni, Peter / Kappetein, A Pieter / Kastrati, Adnan / Knuuti, Juhani / Landmesser, Ulf / Laufer, Günther / Neumann, Franz-Josef / Richter, Dimitrios J / Schauerte, Patrick / Sousa Uva, Miguel / Stefanini, Giulio G / Taggart, David Paul / Torracca, Lucia / Valgimigli, Marco / Wijns, William / Witkowski, Adam. · ·Eur Heart J · Pubmed #25173339.

ABSTRACT: -- No abstract --

4 Editorial Coronary disease prevention: towards a more personalised approach. 2018

Landmesser, Ulf / Catapano, Alberico. ·1 Department of Cardiology, Charité - Universitätsmedizin Berlin, Germany. · 2 Berlin Institute of Health, Germany. · 3 German Center for Cardiovascular Research (DZHK), Germany. · 4 IRCCS MultiMedica, Sesto S Giovanni, Italy. · 5 Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy. ·Eur J Prev Cardiol · Pubmed #30322267.

ABSTRACT: -- No abstract --

5 Editorial A new look at HDL in coronary disease: can we escape natural history? 2011

Gielen, Stephan / Landmesser, Ulf. · ·Heart · Pubmed #21835756.

ABSTRACT: -- No abstract --

6 Review Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. 2019

Sarnak, Mark J / Amann, Kerstin / Bangalore, Sripal / Cavalcante, João L / Charytan, David M / Craig, Jonathan C / Gill, John S / Hlatky, Mark A / Jardine, Alan G / Landmesser, Ulf / Newby, L Kristin / Herzog, Charles A / Cheung, Michael / Wheeler, David C / Winkelmayer, Wolfgang C / Marwick, Thomas H / Anonymous1091188. ·Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. Electronic address: msarnak@tuftsmedicalcenter.org. · Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany. · Division of Cardiology, New York University School of Medicine, New York, New York. · Minneapolis Heart Institute, Minneapolis, Minnesota. · Division of Nephrology, New York University School of Medicine, New York, New York. · College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. · Division of Nephrology, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. · Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California. · Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom. · Department of Cardiology, Charité Universitätsmedizin, Berlin, Germany. · Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. · Division of Cardiology, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota; Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota. · Kidney Disease: Improving Global Outcomes, Brussels, Belgium. · University College London, London, United Kingdom. · Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas. · Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Electronic address: tom.marwick@baker.edu.au. ·J Am Coll Cardiol · Pubmed #31582143.

ABSTRACT: Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research.

7 Review Into the Wild: GWAS Exploration of Non-coding RNAs. 2018

Giral, Hector / Landmesser, Ulf / Kratzer, Adelheid. ·Department of Cardiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. · DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. · Berlin Institute of Health (BIH), Berlin, Germany. ·Front Cardiovasc Med · Pubmed #30619888.

ABSTRACT: Genome-wide association studies (GWAS) have proven a fundamental tool to identify common variants associated to complex traits, thus contributing to unveil the genetic components of human disease. Besides, the advent of GWAS contributed to expose unexpected findings that urged to redefine the framework of population genetics. First, loci identified by GWAS had small effect sizes and could only explain a fraction of the predicted heritability of the traits under study. Second, the majority of GWAS hits mapped within non-coding regions (such as intergenic or intronic regions) where new functional RNA species (such as lncRNAs or circRNAs) have started to emerge. Bigger cohorts, meta-analysis and technical improvements in genotyping allowed identification of an increased number of genetic variants associated to coronary artery disease (CAD) and cardiometabolic traits. The challenge remains to infer causal mechanisms by which these variants influence cardiovascular disease development. A tendency to assign potential causal variants preferentially to coding genes close to lead variants contributed to disregard the role of non-coding elements. In recent years, in parallel to an increased knowledge of the non-coding genome, new studies started to characterize disease-associated variants located within non-coding RNA regions. The upcoming of databases integrating single-nucleotide polymorphisms (SNPs) and non-coding RNAs together with novel technologies will hopefully facilitate the discovery of causal non-coding variants associated to disease. This review attempts to summarize the current knowledge of genetic variation within non-coding regions with a focus on long non-coding RNAs that have widespread impact in cardiometabolic diseases.

8 Review Algorithmic Approach for Optical Coherence Tomography-Guided Stent Implantation During Percutaneous Coronary Intervention. 2018

Shlofmitz, Evan / Shlofmitz, Richard A / Galougahi, Keyvan Karimi / Rahim, Hussein M / Virmani, Renu / Hill, Jonathan M / Matsumura, Mitsuaki / Mintz, Gary S / Maehara, Akiko / Landmesser, Ulf / Stone, Gregg W / Ali, Ziad A. ·Center for Interventional Vascular Therapy, Division of Cardiology, NewYork-Presbyterian Hospital, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA; Department of Cardiology, St. Francis Hospital, 100 Port Washington Boulevard, Suite 105, Roslyn, NY 11576, USA; Clinical Trials Center, Cardiovascular Research Foundation, 1700 Broadway 9th Floor, New York, NY 10019, USA. · Department of Cardiology, St. Francis Hospital, 100 Port Washington Boulevard, Suite 105, Roslyn, NY 11576, USA. · Center for Interventional Vascular Therapy, Division of Cardiology, NewYork-Presbyterian Hospital, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA. · CVPath Institute, 19 Firstfield Road, Gaithersburg, MD 20878, USA. · London Bridge Hospital, 2nd Floor, St Olaf House, London SE1 2PR, UK; Department of Cardiology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. · Clinical Trials Center, Cardiovascular Research Foundation, 1700 Broadway 9th Floor, New York, NY 10019, USA. · Center for Interventional Vascular Therapy, Division of Cardiology, NewYork-Presbyterian Hospital, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA; Clinical Trials Center, Cardiovascular Research Foundation, 1700 Broadway 9th Floor, New York, NY 10019, USA. · Department of Cardiology, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, Berlin 12200, Germany. · Center for Interventional Vascular Therapy, Division of Cardiology, NewYork-Presbyterian Hospital, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA; Department of Cardiology, St. Francis Hospital, 100 Port Washington Boulevard, Suite 105, Roslyn, NY 11576, USA; Clinical Trials Center, Cardiovascular Research Foundation, 1700 Broadway 9th Floor, New York, NY 10019, USA. Electronic address: zaa2112@columbia.edu. ·Interv Cardiol Clin · Pubmed #29983145.

ABSTRACT: Intravascular imaging plays a key role in optimizing outcomes for percutaneous coronary intervention (PCI). Optical coherence tomography (OCT) utilizes a user-friendly interface and provides high-resolution images. OCT can be used as part of daily practice in all stages of a coronary intervention: baseline lesion assessment, stent selection, and stent optimization. Incorporating a standardized, algorithmic approach when using OCT allows for precision PCI.

9 Review High-Density Lipoproteins: Effects on Vascular Function and Role in the Immune Response. 2018

Haghikia, Arash / Landmesser, Ulf. ·Department of Cardiology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin 12203, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Postfach 65 21 33, Berlin 13316, Germany. Electronic address: arash.haghikia@charite.de. · Department of Cardiology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin 12203, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Postfach 65 21 33, Berlin 13316, Germany; Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Straße 2, Berlin 10178, Germany. ·Cardiol Clin · Pubmed #29609761.

ABSTRACT: The focus in studies of high-density lipoproteins was on their capacity to remove excess cholesterol and deliver it to the liver. Other functions and vascular effects have been described. Clinical trials and translational/genetic studies have led to a refined understanding of the role of high-density lipoprotein; it is likely not a causal cardiovascular risk factor. In healthy subjects, it limits lipid oxidation, protects endothelial cell functions/integrity, and exerts antiinflammatory/antiapoptotic effects. In patients with coronary disease or diabetes, it undergoes modifications/remodeling, resulting in dysfunctional high-density lipoprotein. We summarize recent findings about the regulation of its function and discuss the clinical implications.

10 Review Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment. 2018

Stähli, B E / Landmesser, U. ·Department of Cardiology, Charité - Universitätsmedizin Berlin (Benjamin Franklin Campus), Hindenburgdamm 30, 12203, Berlin, Germany. · Deutsches Zentrum für Herz-Kreislaufforschung (DZHK)-Partner Site Berlin, Berlin, Germany. · Department of Cardiology, Charité - Universitätsmedizin Berlin (Benjamin Franklin Campus), Hindenburgdamm 30, 12203, Berlin, Germany. ulf.landmesser@charite.de. · Deutsches Zentrum für Herz-Kreislaufforschung (DZHK)-Partner Site Berlin, Berlin, Germany. ulf.landmesser@charite.de. · Berlin Institute of Health (BIH), Berlin, Germany. ulf.landmesser@charite.de. ·Herz · Pubmed #29236148.

ABSTRACT: The duration and combination of dual antiplatelet therapy after coronary stent implantation, consisting of aspirin and a P2Y12 inhibitor, is among the most intensely investigated therapeutic strategies in cardiovascular medicine. While initial studies have mainly focused on the efficacy and safety of individual antithrombotic agents, the increased need for a personalized, risk-based approach to define the optimal duration of antithrombotic treatment according to the estimated ischemic and bleeding risk was then recognized. Recent recommendations for the optimal duration of antithrombotic combination therapies following coronary stent implantation in various clinical scenarios have substantially changed. The aim of the present article is to discuss the recent evidence from randomized clinical trials and observational studies with respect to antithrombotic treatment regimens in patients undergoing coronary artery stenting for stable coronary artery disease (CAD) or an acute coronary syndrome (ACS). We will focus on optimal treatment duration and a personalized approach based on ischemic and bleeding risk assessment.

11 Review Lipoproteins and Cardiovascular Redox Signaling: Role in Atherosclerosis and Coronary Disease. 2018

Haghikia, Arash / Landmesser, Ulf. ·1 Department of Cardiology, Charité Universitätsmedizin Berlin , Berlin, Germany . · 2 German Center for Cardiovascular Research (DZHK) , partner site Berlin, Berlin, Germany . · 3 Berlin Institute of Health (BIH) , Berlin, Germany . ·Antioxid Redox Signal · Pubmed #28817963.

ABSTRACT: SIGNIFICANCE: Lipoproteins, such as low-density lipoprotein, play a causal role in the development of atherosclerosis and coronary disease. Recent Advances: Lipoproteins can stimulate vascular production of reactive oxygen species, which act as important signaling molecules in the cardiovascular system contributing to the pathophysiology of endothelial dysfunction, hypertension, and atherosclerosis. CRITICAL ISSUES: Modified lipoproteins have emerged as important regulators of redox signaling, such as oxidized or carbamylated low-density lipoprotein or modified high-density lipoproteins, that contain oxidized lipids, an altered protein cargo, and associated small molecules, such as symmetric dimethylarginine. FUTURE DIRECTIONS: In this review, we provide an overview on signaling pathways stimulated by modified lipoproteins in the cardiovascular system and their potential role in cardiovascular disease development. Moreover, we highlight novel aspects of how gut microbiome-related mechanisms-a growing research field-may contribute to lipoprotein modification with subsequent impact on cardiovascular redox signaling. Antioxid. Redox Signal. 29, 337-352.

12 Review Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017

Tenekecioglu, Erhan / Albuquerque, Felipe N / Sotomi, Yohei / Zeng, Yaping / Suwannasom, Pannipa / Tateishi, Hiroki / Cavalcante, Rafael / Ishibashi, Yuki / Nakatani, Shimpei / Abdelghani, Mohammad / Dijkstra, Jouke / Bourantas, Christos / Collet, Carlos / Karanasos, Antonios / Radu, Maria / Wang, Ancong / Muramatsu, Takashi / Landmesser, Ulf / Okamura, Takayuki / Regar, Evelyn / Räber, Lorenz / Guagliumi, Giulio / Pyo, Robert T / Onuma, Yoshinobu / Serruys, Patrick W. ·Erasmus University Medical Centre, Thoraxcenter, Rotterdam, The Netherlands. · Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, United States. · Academic Medical Center-University of Amsterdam, Amsterdam, The Netherlands. · Leiden University Medical Center, Leiden, The Netherlands. · University College of London Hospitals, London, United Kingdom. · Copenhagen University Hospital, Copenhagen, Denmark. · Fujita Health University Hospital, Toyoake, Japan. · Charite Universitätsmedizin Berlin, Berlin, Germany. · Yamaguchi University, Yamaguchi, Japan. · Department of Cardiovascular Surgery, University Hospital Zürich, Switzerland. · Bern University Hospital, Bern, Switzerland. · Ospedali Riuniti di Bergamo, Bergamo, Italy. · Albert Einstein College of Medicine, Montefiore Medical Center, NY. · International Centre for Circulatory Health, Imperial College, London, United Kingdom. ·Catheter Cardiovasc Interv · Pubmed #28109054.

ABSTRACT: By providing valuable information about the coronary artery wall and lumen, intravascular imaging may aid in optimizing interventional procedure results and thereby could improve clinical outcomes following percutaneous coronary intervention (PCI). Intravascular optical coherence tomography (OCT) is a light-based technology with a tissue penetration of approximately 1 to 3 mm and provides near histological resolution. It has emerged as a technological breakthrough in intravascular imaging with multiple clinical and research applications. OCT provides detailed visualization of the vessel following PCI and provides accurate assessment of post-procedural stent performance including detection of edge dissection, stent struts apposition, tissue prolapse, and healing parameters. Additionally, it can provide accurate characterization of plaque morphology and provides key information to optimize post-procedural outcomes. This manuscript aims to review the current clinical and research applications of intracoronary OCT and summarize the analytic OCT imaging software packages currently available. © 2017 Wiley Periodicals, Inc.

13 Review Platelets and coronary artery disease: Interactions with the blood vessel wall and cardiovascular devices. 2016

Reinthaler, Markus / Braune, Steffen / Lendlein, Andreas / Landmesser, Ulf / Jung, Friedrich. ·Department for Cardiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany; Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Helmholtz Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow, Germany; and Joint Laboratory HZG/Charité-FUB, Kantstr. 55, 14513 Teltow, Germany. · Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Helmholtz Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow, Germany. · Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Helmholtz Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow, Germany and Joint Laboratory HZG/Charité-FUB, Kantstr. 55, 14513 Teltow, Germany. · Department for Cardiology, Charité Universitätsmedizin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany and Joint Laboratory HZG/Charité-FUB, Kantstr. 55, 14513 Teltow, Germany. ·Biointerphases · Pubmed #27277200.

ABSTRACT: In view of the rare presence of studies concerning platelet function as risk factor in atherosclerotic patients, processes underlying thromboembolic events are reviewed in this paper. The morphology and the structural organization-membrane receptors, the open canalicular and dense tubular systems, the cytoskeleton, mitochondria, granules, lysosomes, and peroxisomes-of platelets are described. Platelet function under physiological conditions in atherosclerosis and after implantation of cardiovascular devices is summarized.

14 Review [Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update]. 2016

Sinning, D / Leistner, D M / Landmesser, U. ·Klinik für Kardiologie, Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Hindenburgdamm 30, 12203, Berlin, Deutschland. · Berlin Institute of Health (BIH), Berlin, Deutschland. · Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland. · Klinik für Kardiologie, Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Hindenburgdamm 30, 12203, Berlin, Deutschland. ulf.landmesser@charite.de. · Berlin Institute of Health (BIH), Berlin, Deutschland. ulf.landmesser@charite.de. · Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland. ulf.landmesser@charite.de. ·Herz · Pubmed #27215419.

ABSTRACT: Disorders of lipid metabolism play a major role in the development and progression of coronary artery disease. Dyslipidemia therefore plays a central role in therapeutic approaches for prevention and treatment of cardiovascular events associated with coronary artery disease. Epidemiological studies have shown an association between various lipid metabolism parameters, the risk of developing coronary artery disease and progression of a pre-existing disease. In particular, increased levels of low-density lipoprotein cholesterol (LDL-C), reduced levels of HDL cholesterol (HDL-C), as well as high levels of triglycerides and increased lipoprotein(a) [Lp(a)] levels can be taken into account when assessing the risk stratification of patients for primary prevention of coronary artery disease. Lifestyle and dietary changes, intensified statin therapy and possibly the addition of ezetimibe remain the major interventions in both primary and secondary prevention of coronary artery disease, as they improve the prognosis particularly by lowering levels of LDL-C. Recently, genetic studies have contributed to extending our understanding of the relationship between lipid metabolism and coronary artery disease. A causal role for progression of coronary artery disease could be demonstrated for LDL-C, Lpa and triglyceride-rich lipoproteins (TRL), which could not be demonstrated for HDL-C in various studies. Furthermore, the effect of reduction of LDL-C by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and by the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib on cardiovascular events is currently being investigated in large clinical outcome study programs.

15 Review LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics? 2015

Hewing, Bernd / Landmesser, Ulf. ·Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany. ·Curr Cardiol Rep · Pubmed #26031673.

ABSTRACT: Over the past years, genetic studies on lipid traits have substantially extended our understanding of the relationship between lipid metabolism and coronary artery disease (CAD). Thereby, novel pathways and interactions in lipid metabolism unraveled by genetic studies have led to promising novel treatment strategies that are currently evaluated for prevention and treatment of CAD, such as low-density lipoprotein cholesterol (LDL-C) lowering by inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). This review article discusses findings from recent genetic studies and their implications for the understanding of the relation between lipid metabolism and CAD as well as the development of novel therapeutic strategies supported by these studies.

16 Review High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. 2014

Kratzer, Adelheid / Giral, Hector / Landmesser, Ulf. ·Division of Cardiology, University Heart Center, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland Center of Molecular Cardiology, University of Zurich, Zurich, Switzerland. · Division of Cardiology, University Heart Center, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland Center of Molecular Cardiology, University of Zurich, Zurich, Switzerland ulf.landmesser@usz.ch. ·Cardiovasc Res · Pubmed #24935432.

ABSTRACT: Alteration of endothelial cell functions, including reduced endothelial nitric oxide (NO) availability, increased endothelial cell apoptosis, adhesion molecule/chemokine expression and pro-thrombotic activation are thought to contribute to the pathophysiology of atherosclerosis and coronary-artery-disease (CAD) with its clinical complications, such as acute coronary syndromes. High-density lipoproteins (HDL) from healthy subjects or reconstituted HDL have been observed to exert potential direct anti-atherogenic effects by modulating these endothelial cell functions. Importantly, endothelial effects of HDL have now been reported to be highly heterogeneous, and are modulated as part of immune responses. More recently, this has also been observed for HDL of patients with CAD, where HDL becomes potentially pro-inflammatory and endothelial-protective properties are markedly altered. Several mechanisms may lead to these altered endothelial effects of HDL in patients with CAD, including oxidative modification of HDL-associated lipids and proteins, such as apoA-I and paraoxonase-1, and alterations of HDL-proteome. These findings have to be considered with respect to interpretation of recent clinical studies failing to demonstrate reduced cardiovascular events by HDL-cholesterol raising strategies in patients with CAD. Both clinical and genetic studies suggest that HDL-cholesterol levels alone are not a sufficient therapeutic target in patients with CAD. The focus of this review is to summarize the role of HDL onto endothelial homeostasis and to describe recently characterized molecular pathways involved. We highlight how structural and functional modifications of HDL particles in patients with CAD may perturb the physiological homeostasis and lead to a loss of endothelial-protective properties of HDL in patients with CAD.

17 Clinical Trial Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. 2020

Wright, R Scott / Collins, Michael G / Stoekenbroek, Robert M / Robson, Richard / Wijngaard, Peter L J / Landmesser, Ulf / Leiter, Lawrence A / Kastelein, John J P / Ray, Kausik K / Kallend, David. ·Department of Cardiology, Mayo Clinic, Rochester, MN. Electronic address: wright.scott@mayo.edu. · Auckland Clinical Studies Ltd., Auckland, New Zealand; Department of Renal Medicine, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand. · Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; The Medicines Company, Parsippany, NJ. · Christchurch Clinical Studies Trust, Christchurch, New Zealand; Department of Nephrology, Christchurch Hospital, Christchurch, New Zealand. · The Medicines Company, Parsippany, NJ. · Centre for Cardiovascular Diseases, Charité - Universitätsmedizin Berlin, Berlin, Germany. · Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. · Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. · Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK. ·Mayo Clin Proc · Pubmed #31630870.

ABSTRACT: OBJECTIVE: To investigate the pharmacodynamic properties of inclisiran, a small interfering RNA targeting proprotein convertase subtilisin-kexin type 9 (PCSK9), in individuals with normal renal function and renal impairment (RI). PATIENTS AND METHODS: The analysis included participants with normal renal function and mild, moderate, and severe RI from the phase 1 ORION-7 renal study (n=31) and the phase 2 ORION-1 study (n=247) who received 300 mg of inclisiran sodium or placebo. RESULTS: In ORION-7, PCSK9 values were reduced at day 60 in the normal renal function group (68.1%±12.4%), mild RI group (74.2%±12.3%), moderate RI group (79.8%±4.9%), and severe RI group (67.9%±16.4%) (P<.001 vs placebo in all groups). Low-density lipoprotein cholesterol levels were significantly reduced versus placebo: normal renal function, 57.6%±10.7%; mild RI, 35.1%±13.5%; moderate RI, 53.1%±21.3%; severe RI, 49.2%±26.6% (P<.001 for all). In ORION-1, PCSK9 level reductions at day 180 were 48.3% to 58.6% in the 300-mg single-dose groups and 67.3% to 73.0% in the 300-mg 2-dose groups (P<.001 vs placebo in all groups). The corresponding low-density lipoprotein cholesterol level reductions were 35.7% to 40.2% in the 300-mg single-dose groups and 50.9% to 58.0% in the 300 mg 2-dose groups (P<.001 vs placebo in all groups). In ORION-7, exposure to inclisiran was proportionally greater in individuals with increasing RI; inclisiran was undetectable in plasma 48 hours after administration in any group. CONCLUSION: The pharmacodynamic effects and safety profile of inclisiran were similar in study participants with normal and impaired renal function. Dose adjustments of inclisiran are not required in these patients. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT02597127 and NCT03159416.

18 Article Angiography-based quantitative coronary contrast-flow ratio measurements correlate with myocardial ischemia assessed by stress MRI. 2020

Lenk, Karsten / Schwarzbach, Valentin / Antoniadis, Marios / Blum, Maximilian / Zeynalova, Samira / Hagendorff, Andreas / Leistner, David / Landmesser, Ulf / Lavall, Daniel / Laufs, Ulrich. ·Department of Cardiology, University Hospital, Leipzig University, Leipzig, Germany. karsten.lenk@medizin.uni-leipzig.de. · Department of Cardiology, University Hospital, Leipzig University, Leipzig, Germany. · Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Leipzig University, Leipzig, Germany. · Department of Cardiology, Charité Berlin University Medicine, Campus Benjamin Franklin, Berlin, Germany. ·Int J Cardiovasc Imaging · Pubmed #32367188.

ABSTRACT: Contrast-flow quantitative flow ratio (cQFR) is a new technology for quantitative evaluation of coronary stenosis using computational fluid dynamics based on angiograms. The aim of this study was to assess the sensitivity and specificity of cQFR to detect myocardial ischemia using stress magnetic resonance imaging (MRI) as a reference standard. Patients who received stress MRI and coronary angiography were selected from the hospital database. Relevant ischemia on stress MRI was defined as a perfusion deficit in ≥ 2 of 16 segments. cQFR was quantitated based on 3-dimensional quantitative coronary angiography using QAngio XA3D1.1 software by two blinded and independent investigators. A cQFR of ≤ 0.80 was considered abnormal. Among 87 patients 230 vessels met the criteria for full analysis by cQFR (88%). In vascular territories with a significant perfusion deficit, cQFR was significantly lower compared to areas with normal perfusion (0.72 (0.62-0.78) vs. 0.96 (0.89-0.99); p < 0.001). The sensitivity of cQFR in detecting significant epicardial stenoses of coronary vessels with documented ischemia in stress MRI was 81% (68-90%), the specificity was 88% (82-92%). Diameter stenoses (DS) and area stenoses (AS) in vessels with positive stress MRI were significantly higher than in vessels without ischemia (DS 59.1% (49.4-68.4%) vs. 34.8% (27.1-46.1%) p < 0.001; AS 75.6% (63.0-85.2%) vs. 45.0% (30.8-63.6%), p < 0.001). The analysis reveals a high correlation between coronary stenosis measured by cQFR and ischemic areas detected by stress MRI. The data set the stage to plan randomized studies assessing cQFR measurements with regard to clinical outcomes.

19 Article Association of left ventricular end-diastolic pressure with mortality in patients undergoing percutaneous coronary intervention for acute coronary syndromes. 2020

Leistner, David M / Dietrich, Steven / Erbay, Aslihan / Steiner, Julia / Abdelwahed, Youssef / Siegrist, Patrick T / Schindler, Matthias / Skurk, Carsten / Haghikia, Arash / Sinning, David / Riedel, Matthias / Landmesser, Ulf / Stähli, Barbara E. ·Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany. · DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. · Berlin Institute of Health (BIH), Berlin, Germany. · Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. ·Catheter Cardiovasc Interv · Pubmed #32141669.

ABSTRACT: OBJECTIVES: This study sought to investigate the relation between left ventricular end-diastolic pressure (LVEDP) and outcomes in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS). BACKGROUND: Risk stratification in ACS patients is important. Data on the role of LVEDP in the prognostication of ACS patients are scarce. METHODS: A total of 1,410 patients undergoing PCI for ACS and with available data on LVEDP were divided according to LVEDP tertiles (lowest tertile: ≤13 mmHg, intermediate tertile: 14-20 mmHg, and highest tertile: >20 mmHg). The primary endpoint was all-cause mortality at a median follow-up of 246 [28-848] days. RESULTS: Median LVEDP was 16 (11-22) mmHg. All-cause mortality was 2.8%, 4.5%, and 15.0% in the lowest, the intermediate, and the highest LVEDP tertile groups (p < .001), respectively. Belonging to the highest LVEDP tertile was associated with an increased risk of all-cause mortality (adjusted hazard ratio [HR] = 2.66, 95% confidence interval [CI] [1.30, 5.47], p = .008). By receiver operating characteristic curve analysis, the optimal cut-off value for predicting all-cause mortality was 20 mmHg (sensitivity 68.3%, specificity 72.5%). There was no differential effect of LVEDP on mortality in patients with and without LV dysfunction (interaction p = .23) or ST-elevation myocardial infarction as index ACS event (interaction p = .86). CONCLUSIONS: In patients undergoing PCI for ACS, LVEDP was independently related with mortality. Hence, LVEDP should be incorporated into early risk stratification and clinical decision making of ACS patients.

20 Article Comprehensive multimodality characterization of hemodynamically significant and non-significant coronary lesions using invasive and noninvasive measures. 2020

Engel, Leif-Christopher / Landmesser, Ulf / Abdelwahed, Youssef S / Jaguszewski, Milosz / Gigengack, Kevin / Wurster, Thomas-Heinrich / Skurk, Carsten / Manes, Costantina / Schuster, Andreas / Noutsias, Michel / Hamm, Bernd / Botnar, Rene M / Makowski, Marcus R / Bigalke, Boris. ·Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Klinik für Kardiologie, Berlin, Germany. · Berlin Institute of Health (BIH), Berlin, Germany. · Klinik für kardiovaskuläre Erkrankungen, Deutsches Herzzentrum München (DHM), Germany. · Medical University of Gdansk, Gdańsk, Poland. · Department of Cardiology and Pulmonology, Georg-August-University, Göttingen, Germany. · Department of Cardiology, Royal North Shore Hospital, The Kolling Institute, Northern Clinical School, University of Sydney, 5th Floor, Acute Services Building, Reserve Road, St Leonard's, Sydney, Australia. · Mid-German Heart Center, Department of Internal Medicine III (KIM-III), Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle-Wittenberg, Mid-German Heart Center, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. · Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Klinik für Radiologie, Berlin. · King's College London, Division of Imaging Sciences and Biomedical Engineering, London, England, United Kingdom. · Pontificia Universidad Católica de Chile, Escuela de Ingeniería, Santiago, Chile, Germany. ·PLoS One · Pubmed #32004345.

ABSTRACT: BACKGROUND: There is limited knowledge about morphological molecular-imaging-derived parameters to further characterize hemodynamically relevant coronary lesions. OBJECTIVE: The aim of this study was to describe and differentiate specific parameters between hemodynamically significant and non-significant coronary lesions using various invasive and non-invasive measures. METHODS: This clinical study analyzed patients with symptoms suggestive of coronary artery disease (CAD) who underwent native T1-weighted CMR and gadofosveset-enhanced CMR as well as invasive coronary angiography. OCT of the culprit vessel to determine the plaque type was performed in a subset of patients. Functional relevance of all lesions was examined using quantitative flow reserve (QFR-angiography). Hemodynamically significant lesions were defined as lesions with a QFR <0.8. Signal intensity (contrast-to-noise ratios; CNRs) on native T1-weighted CMR and gadofosveset-enhanced CMR was defined as a measure for intraplaque hemorrhage and endothelial permeability, respectively. RESULTS: Overall 29 coronary segments from 14 patients were examined. Segments containing lesions with a QFR <0.8 (n = 9) were associated with significantly higher signal enhancement on Gadofosveset-enhanced CMR as compared to segments containing a lesions without significant stenosis (lesion-QFR>0.8; n = 19) (5.32 (4.47-7.02) vs. 2.42 (1.04-5.11); p = 0.042). No differences in signal enhancement were seen on native T1-weighted CMR (2.2 (0.68-6.75) vs. 2.09 (0.91-6.57), p = 0.412). 66.7% (4 out of 6) of all vulnerable plaque and 33.3% (2 out of 6) of all non-vulnerable plaque (fibroatheroma) as assessed by OCT were hemodynamically significant lesions. CONCLUSION: The findings of this pilot study suggest that signal enhancement on albumin-binding probe-enhanced CMR but not on T1-weighted CMR is associated with hemodynamically relevant coronary lesions.

21 Article Assessment of intermediate coronary lesions by fractional flow reserve and quantitative flow ratio in patients with small-vessel disease. 2019

Erbay, Aslihan / Steiner, Julia / Lauten, Alexander / Landmesser, Ulf / Leistner, David M / Stähli, Barbara E. ·Department of Cardiology, Charité - University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany. · DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. · Berlin Institute of Health (BIH), Berlin, Germany. · Department of Cardiology, University Heart Centre, University Hospital Zurich, Zurich, Switzerland. ·Catheter Cardiovasc Interv · Pubmed #31631499.

ABSTRACT: BACKGROUND: Quantitative flow ratio (QFR) has recently been introduced as a novel, less-invasive, adenosine-free measure for functional coronary lesion assessment. Whether reference vessel dimensions affect functional lesion assessment is uncertain. METHODS: A total of 436 patients with 516 interrogated coronary vessels by means of FFR were included in the study. Patients were dichotomized according to the median reference vessel diameter (group 1: ≤2.8 mm and group 2: >2.8 mm). QFR analyses were performed offline at the institution's core laboratories. RESULTS: Reference vessel diameter was 2.5 [2.3-2.7] mm in group 1 and 3.3 [3.0-3.6] mm in group 2. Diameter stenosis (41.4 [36.4-47.6] % vs. 41.4 [36.4-45.7] %, p = .20) did not differ among groups. Median FFR values were lower in group 1 (0.87 [0.81-0.92]) as compared with group 2 (0.89 [0.84-0.93], p = .001). Consistently, QFR values were lower in group 1 (0.88 [0.82-0.92]) than in group 2 (0.91 [0.85-0.94], p = .001). The proportions of functionally significant coronary lesions as defined by FFR ≤0.80 were 24.1% and 14.2% in groups 1 and 2 (p = .005), and as defined by cQFR ≤0.80 20.4% and 11.8% (p = 0.009), respectively. In ROC analysis for an FFR ≤.80, the AUC was 0.89 (95% CI 0.85-0.93, p < .001) in group 1 and 0.81 (95% CI 0.76-0.86, p < .001) in group 2. CONCLUSIONS: These results suggest that QFR measurements are accurate irrespective of the reference vessel diameter. Future studies are needed to elucidate the higher percentage of functionally significant lesions observed in small vessels despite a similar angiographic lesion severity.

22 Article Systematic use of cardiac magnetic resonance imaging in MINOCA led to a five-fold increase in the detection rate of myocarditis: a retrospective study. 2019

Heidecker, Bettina / Ruedi, Gianni / Baltensperger, Nora / Gresser, Eva / Kottwitz, Jan / Berg, Jan / Manka, Robert / Landmesser, Ulf / Lüscher, Thomas F / Patriki, Dimitri. ·University Hospital Zurich, Switzerland / Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. · University Hospital Zurich, Switzerland. · Department of Anaesthesia and Intensive Care, Kantonsspital St. Gallen, Switzerland. · Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. · University Hospital Zurich, Switzerland / Centre for Molecular Cardiology, University of Zurich, Switzerland / Royal Brompton and Harefield Hospitals and Imperial College, London, United Kindom. ·Swiss Med Wkly · Pubmed #31269222.

ABSTRACT: BACKGROUND: Systematic work-up of patients with myocardial infarction and non-obstructive coronary artery disease (MINOCA) using cardiac magnetic resonance imaging (CMR) led to a more than six-fold increase in the detection rate of myocarditis. In this study, we expanded on our prior two-year analysis by including preceding and subsequent years. METHODS: We performed a retrospective chart review of patients with angina-like symptoms and elevated high-sensitivity troponin T (TnT-hs ≥14 ng/l) but without significant coronary artery disease, from 2011 to 2017. Patients underwent CMR to test for myocarditis. From 2011 to 2015, only patients with elevated TnT-hs, no significant coronary artery disease and moderate to high clinical likelihood of suffering from myocarditis, underwent CMR. In 2016 and 2017, CMR images were obtained from all patients with MINOCA, independent of the clinical likelihood that patients were suffering from myocarditis. RESULTS: A total of 556 patients who underwent CMR (70.5% male, 57 ± 17 years, with an average left ventricular ejection fraction of 51 ± 15%) qualified for inclusion in this study’s analysis. From 2011 to 2015, 240 CMR examinations were performed, with the number increasing to 316 between 2016 and 2017. In total, myocarditis was diagnosed in 76 out of the 556 patients (13.7%). Between 2011 and 2015, the detection rate of myocarditis was 12.7 per 100,000 hospitalisations and increased 4.9-fold (p <0.0001), to 62.5 per 100,000 hospitalisations, between 2016 and 2017. CONCLUSION: A novel diagnostic algorithm led to an average 4.9-fold increase in the rate of myocarditis detection in our hospital over the two subsequent years. This highlights that myocarditis continues to be underdiagnosed when CMR is not systematically used in patients with MINOCA.  .

23 Article Association of the body mass index with outcomes in elderly patients (≥80 years) undergoing percutaneous coronary intervention. 2019

Leistner, David M / Bazara, Sahar / Münch, Charlotte / Steiner, Julia / Erbay, Aslihan / Siegrist, Patrick T / Skurk, Carsten / Lauten, Alexander / Müller-Werdan, Ursula / Landmesser, Ulf / Stähli, Barbara E. ·Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, and Berlin Institute of Health (BIH), Berlin, Germany. · Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany. · Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. · Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. · Department of Geriatrics, Charité Berlin - University Medicine, Research Group on Geriatrics, Berlin, Germany. · Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. Electronic address: barbara-elisabeth.staehli@charite.de. ·Int J Cardiol · Pubmed #31256990.

ABSTRACT: BACKGROUND: The obesity paradox has been recognized in patients with cardiovascular disease. The association between obesity and outcomes in elderly patients undergoing percutaneous coronary intervention (PCI) has not been investigated, yet. METHODS: A total of 990 elderly (≥80 years) patients undergoing PCI at our institution between January 2009 and December 2017 and with available data on body mass index (BMI) were divided according to BMI tertiles (lowest BMI tertile: ≪24.1 kg/m RESULTS: All-cause mortality was 11.2%, 7.6%, and 5.8% in the lowest, the middle, and the highest BMI tertiles (Log Rank p = 0.008). Belonging to the lowest BMI tertile was associated with an increased risk of all-cause mortality (HR 2.14, 95% CI 1.23-3.73, p = 0.007), and associations remained significant after multivariable adjustments (adjusted HR 1.92, 95% CI 1.05-3.52, p = 0.03). While belonging to the lowest BMI tertile was independently associated with an increased all-cause mortality in patients with acute coronary syndromes (HR 2.32, 95% CI 1.24-4.35, p = 0.009; adjusted HR 2.40, 95% CI 1.19-4.84, p = 0.01), relations were not significant in patients with stable coronary artery disease (HR 1.32, 95% CI 0.38-4.56, p = 0.67; adjusted HR 0.80, 95% CI 0.21-3.05, p = 0.75). CONCLUSIONS: In elderly (≥80 years) patients undergoing PCI, belonging to the lowest BMI tertile was associated with an increased mortality, mainly in acute coronary syndromes. Hence, the BMI should be incorporated into the risk stratification of elderly patients with coronary artery disease.

24 Article LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. 2019

Silbernagel, Günther / Scharnagl, Hubert / Kleber, Marcus E / Delgado, Graciela / Stojakovic, Tatjana / Laaksonen, Reijo / Erdmann, Jeanette / Rankinen, Tuomo / Bouchard, Claude / Landmesser, Ulf / Schunkert, Heribert / März, Winfried / Grammer, Tanja B. ·Division of Angiology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria; Department of Cardiology, Charité Berlin (CBF), Berlin Institute of Health (BIH), And DZHK (German Research Centre for Cardiovascular Research), Partner Site Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. · Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria. Electronic address: hubert.scharnagl@medunigraz.at. · Department of Internal Medicine 5 (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Mannheim Medical Faculty, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. · Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria. · Zora Biosciences Oy, Espoo, Finland; Finnish Cardiovascular Research Center Tampere, University of Tampere, Finland; Finnish Clinical Biobank, University Hospital of Tampere, Finland. · Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany; DZHK (German Research Centre for Cardiovascular Research), Partner Site Hamburg/Lübeck/Kiel, Lübeck, Germany; University Heart Center Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. · Human Genomics Laboratory, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA, 70808, United States. · Department of Cardiology, Charité Berlin (CBF), Berlin Institute of Health (BIH), And DZHK (German Research Centre for Cardiovascular Research), Partner Site Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. · Department of Cardiology, German Heart Center Munich, Technical University Munich and DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Lazarettstraße 36, 80636, Munich, Germany. · Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria; Synlab Academy, Synlab Holding Germany GmbH, P5, 7, 68167, Mannheim, Germany; Department of Internal Medicine 5 (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Mannheim Medical Faculty, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. · Mannheim Institute of Public Health, Mannheim Medical Faculty, University of Heidelberg, Ludolf-Krehl-Straße 7-11, 68167, Mannheim, Germany. ·Atherosclerosis · Pubmed #30685440.

ABSTRACT: BACKGROUND AND AIMS: High concentrations of low density lipoprotein (LDL) triglycerides have been associated with prevalent angiographic coronary artery disease. The present analysis was designed to investigate the association of LDL triglycerides with cardiovascular mortality and to explore possible mechanisms that may link LDL triglycerides to cardiovascular risk. METHODS: LDL triglycerides were measured in 3140 participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. They were prospectively followed for cardiovascular mortality (median duration 9.9 years). Genome wide association data for LDL triglycerides were available for 2900 LURIC participants. Genetic data and measurements of hepatic lipase activity were available for 478 participants of the HERITAGE Family study. Genome wide association data for cardiovascular disease were available for 184,305 participants of the CARDIoGRAMplusC4D consortium. RESULTS: There was a continuous positive association between LDL triglycerides and cardiovascular mortality (hazard ratio for 5th vs. 1st quintile = 2.53, p < 0.001) and this association was similar in males and females. Genome wide association analysis in LURIC revealed that LDL triglycerides were strongly associated with variation in the hepatic lipase region (p < 10 CONCLUSIONS: Low hepatic lipase activity may link high LDL triglycerides to increased cardiovascular risk.

25 Article Comparison of resting distal to aortic coronary pressure with angiography-based quantitative flow ratio. 2019

Stähli, Barbara E / Erbay, Aslihan / Steiner, Julia / Klotsche, Jens / Mochmann, Hans-Christian / Skurk, Carsten / Lauten, Alexander / Landmesser, Ulf / Leistner, David M. ·Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. · German Rheumatism Research Center Berlin, Berlin, Germany; Institute for Epidemiology and Health Care Economics, Charité Berlin - University Medicine, Campus Mitte, Berlin, Germany. · Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany. · Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany. Electronic address: david-manuel.leistner@charite.de. ·Int J Cardiol · Pubmed #30545620.

ABSTRACT: BACKGROUND: Quantitative flow ratio (QFR) is a novel, adenosine-free method for functional coronary lesion interrogation, which is based on 3-dimensional quantitative coronary angiography and computational algorithms. Data on QFR in all-comer patients with intermediate coronary lesions are scarce, and the diagnostic performance in comparison to resting distal to aortic coronary pressure (Pd/Pa) ratio unknown. METHODS: A total of 436 patients with 516 vessels undergoing FFR measurements were included in the analysis. Diagnostic performance of QFR, distal to aortic coronary pressure (Pd/Pa) ratio, and anatomic indices versus FFR was assessed. RESULTS: FFR ≤0.80 was measured in 19.4% of interrogated vessels. QFR significantly correlated with FFR (r = 0.82, p < 0.001) with good agreement between QFR and FFR (mean difference 0.011, 95% CI 0.008-0.015). The AUC for an FFR ≤0.80 was 0.86 (95% CI 0.83-0.89, p < 0.001) for QFR, 0.76 (0.72-0.80, p < 0.001) for resting Pd/Pa ratio, and 0.63 (0.59-0.67, p < 0.001) for diameter stenosis. The diagnostic accuracy for identifying an FFR ≤0.80 was 93.4% for QFR, 84.3% for resting Pd/Pa ratio, and 80.4% for diameter stenosis. CONCLUSIONS: QFR provides a novel diagnostic tool for functional coronary lesion assessment with superior diagnostic accuracy as compared with resting Pd/Pa ratio and anatomic indices. Future studies are needed to determine the non-inferiority of QFR analysis to FFR assessment with respect to clinical outcomes.

Next